Active Funding Opportunities:

RFAs

  • RFA-HG-20-014: Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
  • RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)
  • RFA-HG-20-016: Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)
  • RFA-HG-21-001: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)
  • RFA-HG-21-002: Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)
  • RFA-HG-21-006: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)
  • RFA-HG-21-007: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)
  • RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)

PAR

  • PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)

Notice of Special Interest (NOSI)

  • NOT-HG-21-018: Advancing Genomic Technology Development for Research and Clinical Application

Inactive Funding Opportunities:

RFAs

  • RFA-HG-20-019: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
  • RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
  • RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
  • RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

PARs

  • PAR-18-777: Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
  • PAR-18-778: Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
  • PAR-18-779: Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)

Updated 7/22/2021